In other pharmaceutical news this week, the evidence review committee for NICE (the National Institute for Health and Clinical Excellence) issued a final appraisal determination on the diet drug Acomplia (rimonabant) that surprised the world. It reversed its December draft technology appraisal recommending against the diet drug. Yesterday, NICE recommended the diet drug become part of UK’s
